Home » PFIZER RECEIVES EUROPEAN APPROVAL TO MARKET AROMASIN(R)
PFIZER RECEIVES EUROPEAN APPROVAL TO MARKET AROMASIN(R)
Pfizer Inc said today that it has received European Mutual Recognition Procedure (MRP) approval to market Aromasin(R) (exemestane tablets) for a new indication, adjuvant treatment of estrogen receptor positive invasive early breast cancer following two-to-three years of initial adjuvant tamoxifen therapy in postmenopausal women. Aromasin is a hormonal therapy, used to treat women with breast cancers that depend on a hormone, specifically estrogen, for growth and survival. An estimated two-thirds of breast cancer cases are estrogen-dependent.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-13-2005/0004106076&EDATE=)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May